Navigation Links
EntreMed Presents Mechanism Data for Its Three Lead Oncology,Compounds

mation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell cycle regulator, is in Phase 2 studies for cancer. ENMD-1198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
10. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
11. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
Post Your Comments:
(Date:7/2/2015)... DALLAS , July 2, 2015 ... Market by Technology (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial ... Trends & Global Forecast to 2020", published by MarketsandMarkets, the ... and is projected to reach $6.20 Billion by 2020, at ... Browse 8 4 market ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ) has announced the ... by Application - Forecast to 2020" report to their offering. ... $13.1 Billion in 2020 from an estimated $7.1 Billion in 2015, ... dominated by North America , followed by ... of the World (RoW). The cancer diagnostics market in ...
(Date:7/2/2015)... SAN FRANCISCO , July 2, 2015  The ... www.tryloud.com ), the world,s first HIPAA compliant mobile app ... delivery of farm-to-table fresh medical marijuana, announced today that ... Unlike Eaze, Meadow and more than half ... in the last year, Loud Cannabis is unique in ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2
... 2007 - OXiGENE, Inc.,(NASDAQ: OXGN, XSSE: OXGN), a ... and eye,diseases, announced today the publication of two ... afternoon at the,Annual Meeting of the American Society ... abstract reports for the first time full data ...
... June 04, 2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences Incorporated ... trial showing that tanespimycin demonstrated antitumor,activity and ... patient with a BRAF mutation (V600E) who ... initiation) and while on,tanespimycin demonstrated progression-free survival ...
Cached Medicine Technology:OXiGENE Abstracts Published in ASCO Program 2OXiGENE Abstracts Published in ASCO Program 3OXiGENE Abstracts Published in ASCO Program 4Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 2Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 3Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 4
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... The ZAC ... the 2015 swim season with important lessons on how to stay water safe with ... Who Couldn’t, Wouldn’t Swim, authored by The ZAC Foundation co-founders, follows Zeke’s water safety ...
(Date:7/2/2015)... PLAINSBORO, N.J. (PRWEB) , ... July 02, 2015 ... ... ACO and Emerging Healthcare Delivery Coalition met for the late June Web-based ... moves forward with new reimbursement schemes and managing high-risk patients through coordinated care. ...
(Date:7/2/2015)... La Mirada, CA (PRWEB) , ... July 02, ... ... the addition of Dr. Divakar R. Krishnareddy, M.D., to the orthopedic and spine ... fractures, dislocations, disc herniations, sprains, strains, bursitis, and tendonitis. Along with the spine ...
(Date:7/2/2015)... , ... July 02, 2015 , ... ... executing them with care and precision. There is an art and science that ... the honor of successfully reshaping the facial features and lives of more than ...
(Date:7/2/2015)... NY (PRWEB) , ... July 02, 2015 , ... ... for Carpal Tunnel treatment and wrist pain treatment. Dr. Lev Kalika, founder of ... – and a leading international authority on the conservative treatment of back, hip, ...
Breaking Medicine News(10 mins):Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 4Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4
... Disease at A Young Age, Tells His Story ... Inc. (NYSE: MDT ), announced it ... to raise awareness among individuals with Parkinson,s disease ... lives today. Together, through educational programs focused on ...
... New promotion encourages funding future college tuition for as ... -- Starting today, College ... 529 prepaid tuition program launches its "57 Reasons" Incentive ... at 2008-,09 contract prices, the incentive program makes the ...
... culture media components will reveal significant advantages of its products at ... San Francisco. , ... Fort Collins, CO (PRWEB) April ... components used for mammalian cell culture will be showcased at the ...
... Efforts to Contain Measles Outbreak ContinueHARRISBURG, Pa., April 9 ... County Health Department, in coordination with UPMC,s Children,s Hospital ... measles outbreak was a traveler from India who arrived ... confirmed measles cases in southwestern Pennsylvania now totals six, ...
... Rockville MD The Association for Research in Vision and ... Five individuals will be recognized at the ARVO Annual Meeting, ... The Proctor Medal: Joe G. Hollyfield, The Friedenwald: Award ... Alan Bird, The Cogan Award: Marie Burns, The Kupfer Award: ...
... published tomorrow (10 April) in Science examines ... bowel disease, rheumatoid arthritis and asthma and has shown ... responses to infection and maintain inflammation in the body. ... drugs to treat these conditions. , Scientists funded by ...
Cached Medicine News:Health News:Video: Davis Phinney Foundation and Medtronic Raise Awareness of How to Improve Your Life Today for Those Living With Parkinson's Disease 2Health News:Video: Davis Phinney Foundation and Medtronic Raise Awareness of How to Improve Your Life Today for Those Living With Parkinson's Disease 3Health News:57 (More) Reasons to Buy a Contract From College Illinois!(SM) 2Health News:57 (More) Reasons to Buy a Contract From College Illinois!(SM) 3Health News:InVitria Headlines Sponsorship of WilBio's Waterside Conference 2Health News:Health Officials Identify Source of Measles, Additional Places of Possible Exposure 2Health News:Health Officials Identify Source of Measles, Additional Places of Possible Exposure 3Health News:ARVO 2009 award recipients 2Health News:ARVO 2009 award recipients 3Health News:Biological FM signal maintains inflammation in cancer, asthma and other diseases 2
A three lamp light source maximizes use by allowing two surgeons to work simultaneously from it, while the third lamp is reserved for backup....
Cold light source single outlet....
Cold light source dual outlet....
The 9100 is a truly affordable 100 Watt xenon light source providing accurate color and brightness. This xenon light source is ideal for surgery centers, evaluations or general office use....
Medicine Products: